COCP - Cocrystal Pharma oral antiviral CC-42344 for influenza A shows safety in interim phase 1 data

Cocrystal Pharma (NASDAQ:COCP) said preliminary data from a phase 1 study of CC-42344 showed a favorable safety and pharmacokinetic profile of the oral antiviral for pandemic and seasonal influenza A. The company said the ongoing phase 1 trial plans to enroll 56 healthy adults. Results from the first two single-ascending dose 100 mg and 200 mg groups showed a favorable pharmacokinetic profile of CC-42344. The company added that to date, CC-42344, has shown oral bioavailability, dose-dependent plasma exposures, and a half-life supportive of oral daily dosing. Cocrystal (COCP) expects to report full results from the study in 2022. COCP +5.88% to $0.54 premarket April 12

For further details see:

Cocrystal Pharma oral antiviral CC-42344 for influenza A shows safety in interim phase 1 data